Mersana Therapeutics Inc (MRSN) concluded trading on Wednesday at a closing price of $0.46, with 3.48 million shares of worth about $1.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -76.70% during that period and on Wednesday the price saw a loss of about -2.15%. Currently the company’s common shares owned by public are about 115.65M shares, out of which, 85.81M shares are available for trading.
Stock saw a price change of -10.05% in past 5 days and over the past one month there was a price change of -21.24%. Year-to-date (YTD), MRSN shares are showing a performance of -67.90% which decreased to -90.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.44 but also hit the highest price of $5.11 during that period. The average intraday trading volume for Mersana Therapeutics Inc shares is 5.66 million. The stock is currently trading -9.17% below its 20-day simple moving average (SMA20), while that difference is down -25.91% for SMA50 and it goes to -71.52% lower than SMA200.
Mersana Therapeutics Inc (NASDAQ: MRSN) currently have 115.65M outstanding shares and institutions hold larger chunk of about 54.62% of that.
The stock has a current market capitalization of $57.20M and its 3Y-monthly beta is at 1.54. It has posted earnings per share of -$0.57 in the same period. It has Quick Ratio of 2.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRSN, volatility over the week remained 9.28% while standing at 10.21% over the month.
Stock’s fiscal year EPS is expected to drop by -28.16% while it is estimated to increase by 9.05% in next year. EPS is likely to shrink at an annualized rate of -13.09% for next 5-years, compared to annual growth of 2.74% made by the stock over the past 5-years.
Coverage by Citigroup stated Mersana Therapeutics Inc (MRSN) stock as a Buy in their note to investors on November 15, 2024, suggesting a price target of $5 for the stock. On March 19, 2024, JP Morgan Upgrade their recommendations, while on February 29, 2024, Wedbush Upgrade their ratings for the stock with a price target of $7. Stock get a Buy rating from Guggenheim on February 29, 2024.
